April 21, 2020 07:01 AM EDTUpdated 08:15 AM
R&D

An­oth­er PhI­II win in hand, Cara aims straight for pri­or­i­ty re­view of 'break­through' pru­ri­tus drug

Amber Tong

Cara Ther­a­peu­tics has cleared the fi­nal hur­dle be­tween its lead pro­gram and an NDA fil­ing, hit­ting the pri­ma­ry end­point on its sec­ond Phase III tri­al …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

Adap­ti­m­mune's sec­ond T cell re­cep­tor cell ther­a­py for rare sar­co­mas pass­es piv­otal test

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times